RT info:eu-repo/semantics/article
T1 TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status
A1 Herreros-Villanueva, Marta
A1 Muñiz Rodríguez, Pilar
A1 García Girón, Carlos
A1 Cavia Saiz, Mónica
A1 Coma del Corral, María J.
K1 Salud
K1 Health
K1 Biología molecular
K1 Molecular biology
AB Background: Although there have been many studies on the p73 gene, some of its functions still remain unclear.There is little research on the relationship between p73 gene transcription and its protein expression and theresponse to certain drugs such as oxaliplatin and cetuximab, which are drugs currently used in colorectal cancer.The purpose of this study was to evaluate the impact of TAp73 expression on oxaliplatin and cetuximab-basedchemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status.Methods: TAp73 was analyzed in three colorectal tumor cell lines HT-29, SW-480 and Caco-2. mRNA TAp73 wasdetermined using Real time PCR; TAp73 protein by immunoblotting and cell viability was analyzed by the MTTmethod.Results: We found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin (in monotherapyor combined with cetuximab) when B-Raf is mutated. This was statistically significant and was also associated withhigher cell viability after the treatment.Conclusions: Here, for the first time we report, that there is a signaling loop between B-Raf activation and p73function.Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of responseto oxaliplatin in monotherapy or combined with cetuximab.
PB Springer Nature
YR 2010
FD 2010-02
LK http://hdl.handle.net/10259/8072
UL http://hdl.handle.net/10259/8072
LA eng
NO We thank B. De La Nogal and the Pharmacy Department for their generous help. Also, we thank CMV and her group in Leon. This work was supported by a grant FIS CA08/00070 from Instituto de Salud Carlos III, Spanish Ministerio de Ciencia e Innovación to MHV and Fundación Burgos por la Investigación de la Salud. MHV is especially thankful to CVP, IHH and AHV, for their support.
DS Repositorio Institucional de la Universidad de Burgos
RD 11-may-2024